ClinicalTrials.Veeva

Menu

Obstetrical History and Anti-HLA Antibodies Level (OBS-HLA)

A

Assistance Publique - Hôpitaux de Paris

Status

Enrolling

Conditions

Anti-HLA Antibody
Blood Donors

Treatments

Other: Obstetrical history
Other: Anti-HLA Antibody tests

Study type

Observational

Funder types

Other

Identifiers

NCT06021925
APHP221333
2021-A01199-32 (Registry Identifier)

Details and patient eligibility

About

Chronic histiocytic intervillositis (CHI) is associated with severe and recurrent obstetrical complications. A link between anti-HLA Antibodies (Ab) and CHI has recently been established. At the Etablissement Français du Sang (EFS), donors who have already given birth once and have high levels of anti-HLA are excluded from donating apheresis platelets and therapeutic plasma to prevent TRALI (Transfusion Related Acute Lung Injury). No studies have examined the obstetrical history of these donors. The question is: is there an association between anti-HLA levels and obstetrical complications?

Full description

Chronic histiocytic intervillositis (CHI) is a rare condition with an incidence of around 5 in 10,000 pregnancies. It is defined by major infiltration of the intervillous cavity by CD68+ maternal histiocytes, associated with fibrin deposition on the villous surface.

CHI is associated with severe obstetrical complications and a very high recurrence rate, estimated at between 70% and 100%. These complications include early and late miscarriage, fetal death, severe growth retardation in surviving fetuses, and premature delivery. The survival rate reported in the literature varies between 30% and 50%.

Anti-HLA antibodies are present in 54% of pregnant women at the end of pregnancy, and their rate increases towards the end of pregnancy. The presence of HLA antibodies also increases with the number of pregnancies, and is found in up to 74% of cases after more than 2 deliveries.

The research question concerns the existence of a statistically significant association between the presence of high levels of anti-HLA antibodies and the occurrence of one or more obstetric complications.

Enrollment

6,000 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Female blood donors who have been tested for anti-HLA antibodies in the context of TRALI prevention between 2010 and 2020 at EFS Nouvelle Aquitaine [The donors meet the conditions of the Order of December 17, 2019 establishing the selection criteria for blood donors and are over 18 years old, are not protected persons and understand French well]
  • Women who have already given birth at least once (non-nulliparous women)
  • Women who have not expressed their opposition at the time of donation to participating in a research project and to be contacted

Exclusion criteria

  • None [Donors meet the conditions of the Order of December 17, 2019 establishing the selection criteria for blood donors and are over 18 years old, are not protected persons and understand French well]

Trial design

6,000 participants in 1 patient group

Blood donors tested for anti-HLA Antibody
Description:
Blood donors tested for anti-HLA Antibody between 2010 and 2020 as part of TRALI prevention program.
Treatment:
Other: Anti-HLA Antibody tests
Other: Obstetrical history

Trial contacts and locations

1

Loading...

Central trial contact

Isabelle JOLLET; Xavier LAFARGE, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems